News Sentiment

ANRO sentiment intelligence

Alto Neuroscience, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 30 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 26.48 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

72/100 classification confidence.

Company focus 22

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+6.9% over one week, +23.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 72/100 classification
One-week reaction 6.9% Price confirming higher
Trend fit Trend active 23.3% over four weeks
Fair value 139.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 10
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 22
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
The National Law Review 5
TradingView 4
Stock Titan 3
Insider Monkey 2
simplywall.st 2
Minichart 1
Moomoo 1

Event Lens

What the news is about

Classified themes
Earnings 12
Market update 8
Regulatory and legal 4
Analyst action 3
Balance sheet 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 30
Minichart Direct company coverage

Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE

Alto Neuroscience (NYSE: ANRO) has announced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, aiming to raise approximately $100 million in gross proceeds. The offering is managed by BofA Securities and Stifel, Nicolaus & Company

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 16:12
Source
Minichart
Stock Titan Direct company coverage

Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale

Alto Neuroscience (NYSE: ANRO) announced it will raise approximately $93.9 million through an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share. The company plans to use these net proceeds, along with existing cash, to expand the clin

Tone
Positive 66/100
Event
Balance sheet
Published
14 Jul 2026 10:13
Source
Stock Titan
Latham & Watkins LLP Direct company coverage

Latham Advises on Alto Neuroscience’s US$100 Million Underwritten Registered Direct Offering of Common Stock

Latham & Watkins LLP is advising the underwriters for Alto Neuroscience, Inc.'s underwritten registered direct offering of 3,776,436 shares of common stock. The offering is priced at US$26.48 per share, expecting to generate approximately US$100 million in gross proceeds. The dea

Tone
Positive 70/100
Event
Market update
Published
13 Jul 2026 17:09
Source
Latham & Watkins LLP
Stock Titan Direct company coverage

Alto Neuroscience (NYSE: ANRO) estimates $244.2M cash and plans added ALTO-207 Phase 3

Alto Neuroscience (NYSE: ANRO) reported a preliminary estimate of approximately $244.2 million in cash, cash equivalents, and restricted cash as of June 30, 2026. This unaudited figure is subject to change after the completion of accounting procedures. Additionally, the company a

Tone
Positive 66/100
Event
Balance sheet
Published
13 Jul 2026 13:15
Source
Stock Titan
Business Wire Direct company coverage

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience (NYSE: ANRO) announced the pricing of a $100.0 million registered direct offering of 3,776,436 shares of its common stock at $26.48 per share. The company plans to use the proceeds, along with existing cash, to accelerate and expand the clinical development of A

Tone
Positive 72/100
Event
Balance sheet
Published
13 Jul 2026 11:46
Source
Business Wire
TradingView Direct company coverage

Alto Neuroscience, Inc. Stock 12‑Month Price Target Cut to $34.8, Implies 33% Upside

Analysts have slightly lowered their average 12-month price target for Alto Neuroscience, Inc. (ANRO) stock from $35.11 to $34.80, with a range of $24 to $50 per share. Despite the slight reduction, the updated target still suggests a 33% potential upside based on the July 8 clos

Tone
Positive 71/100
Event
Analyst action
Published
09 Jul 2026 04:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO

This article provides the "Price to earnings forward" value for Alto Neuroscience, Inc. (NYSE: ANRO). It indicates that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial metric for ANRO.

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 03:41
Source
TradingView
The National Law Review Direct company coverage

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (NYSE: ANRO) announced its participation in two upcoming investor conferences in May and June 2026. The company's management team will present at the Bank of America Securities Healthcare Conference and the Jefferies Global Healthcare Conference, with webc

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 22:09
Source
The National Law Review
Insider Monkey Direct company coverage

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

Alto Neuroscience, Inc. (ANRO) shows promise for growth following new insights into anhedonia treatment and strategic board appointments. A study published in Nature Medicine highlighted the effectiveness of pramipexole, a dopamine agonist, in reducing anhedonia in patients with

Tone
Positive 71/100
Event
Market update
Published
02 Jul 2026 20:09
Source
Insider Monkey
Insider Monkey Direct company coverage

5 Best Up and Coming Pharmaceutical Stocks to Buy Now

This article identifies Alto Neuroscience, Inc. (NYSE:ANRO) as one of the top up-and-coming pharmaceutical stocks. The company recently highlighted the publication of positive results from an independent study on pramipexole for mood disorders in Nature Medicine, showing signific

Tone
Positive 72/100
Event
Earnings
Published
30 Jun 2026 18:03
Source
Insider Monkey
www.marketscreener.com Direct company coverage

Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index

Alto Neuroscience, Inc. (NYSE:ANRO) has been added to the Russell 2000 Index, reflecting its growing presence in the market. The company, a clinical-stage biopharmaceutical firm, focuses on precision psychiatry by using neurobiology and brain biomarkers to develop personalized tr

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 22:10
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark

Alto Neuroscience, Inc. (NYSE: ANRO) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. The company, a clinical-stage biopharmaceutical firm, focuses on personalized psychiatry treatments through its Precision Psychiatry

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 20:03
Source
marketscreener.com
The National Law Review Direct company coverage

Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol

Levi & Korsinsky is notifying shareholders of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit with a deadline of September 19, 2025. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness of its product pipeline, ALTO-100, for tre

Tone
Negative 20/100
Event
Regulatory and legal
Published
28 Jun 2026 20:40
Source
The National Law Review
The National Law Review Direct company coverage

Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Shareholders of Class Action Lawsuit And September 19, 2025 Deadline

Levi & Korsinsky has announced a class action lawsuit against Alto Neuroscience, Inc. (ANRO) for shareholders who purchased stock between February 2, 2024, and October 22, 2024. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiv

Tone
Negative 29/100
Event
Regulatory and legal
Published
28 Jun 2026 13:40
Source
The National Law Review
The National Law Review Direct company coverage

Securities Lawsuit Alert: Alto Neuroscience, Inc. (ANRO) - Contact Levi & Korsinsky Before September 19, 2025

Levi & Korsinsky, LLP has issued a securities lawsuit alert for investors who suffered losses in Alto Neuroscience, Inc. (NYSE:ANRO) stock. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and commercial prospects of its product pipelin

Tone
Negative 18/100
Event
Regulatory and legal
Published
27 Jun 2026 12:09
Source
The National Law Review
The Globe and Mail Direct company coverage

H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Alto Neuroscience, Inc. (ANRO) and set a $50.00 price target. This recommendation comes despite the company reporting an increased GAAP net loss of $26.24 million for the quarter ending March 31, compared to $15

Tone
Positive 76/100
Event
Analyst action
Published
26 Jun 2026 13:10
Source
The Globe and Mail
TradingView Direct company coverage

Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO)

This article provides key financial data and analyst estimates for Alto Neuroscience, Inc. (ANRO). It details the company's stock ticker, analyst price forecasts, historical high and low stock prices, and upcoming earnings report dates. Additionally, it covers last quarter's earn

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 12:11
Source
TradingView
The National Law Review Direct company coverage

Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi

Levi & Korsinsky LLP is reminding investors of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit stemming from the company's initial public offering around February 2, 2024. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and

Tone
Negative 20/100
Event
Regulatory and legal
Published
26 Jun 2026 11:39
Source
The National Law Review
Simply Wall Street Direct company coverage

Alto Neuroscience (NYSE:ANRO) Stock Forecast & Analyst Predictions

Alto Neuroscience (NYSE:ANRO) is forecast to see a decline in earnings at 1.9% annually, while revenue is projected to grow by 73.7% per year. The company is actively developing several drug candidates, including ALTO-207 for treatment-resistant depression which is entering Phase

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 04:41
Source
Simply Wall Street